Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond
SAGE Open Medicine · 2024-01 · 12
DOI: 10.1177/20503121241257486 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift SAGE Open Medicine, online erschienen am 31.05.2024. Verfasst von Zenawork Sahle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, Asrat Weldeyes Health Science Campus, Debre Berhan University, Debre Berhan, Ethiopia. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The human microbiome, particularly the gut microbiome, has emerged as a central determinant of health and disease. Dysbiosis, an imbalance in the microbial composition of the gut, is associated with a variety of metabolic and other diseases, highlighting the potential for microbiota-targeted treatments. Fecal microbiota transplantation has received considerable attention as a promising therapy to modulate the gut microbiome and restore microbial homeostasis. However, challenges remain, including standardization, safety, and long-term efficacy. This review summarizes current knowledge on fecal microbiota transplantation and describes the next generation therapies targeting microbiome. This review looked at the mechanistic understanding of fecal microbiota transplantation and alternative strategies, elucidating their potential role in improving dysbiosis-associated metabolic disorders, such as obesity, and type 2 diabetes and others. Additionally, this review discussed the growing application of therapies targeting the gut microbiome. Insights from clinical trials, preclinical studies, and emerging technologies provide a comprehensive overview of the evolving landscape of microbiome-based interventions. Through a critical assessment of current advances and prospects, this review aims to highlight the therapeutic potential of targeting gut microbiome and pave the way for innovative approaches in precision medicine and personalized treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Science, Asrat Weldeyes Health Science Campus, Debre Berhan University, Debre Berhan, Ethiopia.
- Department of Medical Laboratory Science, Debre Berhan Compressive Specialized Hospital, Debre Berhan, Ethiopia.
ORCID-Profile: Zenawork Sahle, Demissew Shenkute Gebreyes, Tsegahun Asfaw Abebe
Zitieren
APA
Sahle, Z., Engidaye, G., Shenkute Gebreyes, D., Adenew, B., & Abebe, T. A. (2024). Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond. SAGE Open Medicine, 12. https://doi.org/10.1177/20503121241257486
Vancouver
Sahle Z, Engidaye G, Shenkute Gebreyes D, Adenew B, Abebe TA. Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond. SAGE Open Medicine. 2024;12. doi:10.1177/20503121241257486
BibTeX
@article{Sahle2024,
author = {Sahle, Zenawork and Engidaye, Getabalew and Shenkute Gebreyes, Demissew and Adenew, Behailu and Abebe, Tsegahun Asfaw},
title = {Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond},
journal = {SAGE Open Medicine},
year = {2024},
volume = {12},
doi = {10.1177/20503121241257486}
}
EUVIMED